Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.6940
-0.0260 (-3.61%)
At close: Apr 1, 2025, 4:00 PM
0.6847
-0.0093 (-1.34%)
After-hours: Apr 1, 2025, 4:06 PM EDT
Spero Therapeutics Revenue
In the year 2024, Spero Therapeutics had annual revenue of $47.98M, down -53.77%. Spero Therapeutics had revenue of $15.04M in the quarter ending December 31, 2024, a decrease of -79.54%.
Revenue (ttm)
$47.98M
Revenue Growth
-53.77%
P/S Ratio
0.81
Revenue / Employee
$1,042,978
Employees
46
Market Cap
38.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SPRO News
- 4 days ago - Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewsWire
- 14 days ago - Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 - GlobeNewsWire
- 5 weeks ago - UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal - Seeking Alpha
- 2 months ago - Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - GlobeNewsWire
- 4 months ago - Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewsWire